WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008102716) AGENT FOR TREATMENT OF ADHD-RELATED DISEASES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/102716    International Application No.:    PCT/JP2008/052611
Publication Date: 28.08.2008 International Filing Date: 18.02.2008
IPC:
A61K 31/585 (2006.01), A23L 1/30 (2006.01), A61K 31/7048 (2006.01), A61P 25/08 (2006.01), A61P 25/18 (2006.01), A61P 25/20 (2006.01), A61P 25/22 (2006.01), A61P 25/28 (2006.01), C07J 17/00 (2006.01)
Applicants: MEIJI DAIRIES CORPORATION [JP/JP]; 2-10, Shinsuna 1-chome, Koto-ku, Tokyo 1368908 (JP) (For All Designated States Except US).
TOHDA, Chihiro [JP/JP]; (JP) (For US Only).
YAMADA, Masashi [JP/JP]; (JP) (For US Only).
SUZUKI, Hiroto [JP/JP]; (JP) (For US Only)
Inventors: TOHDA, Chihiro; (JP).
YAMADA, Masashi; (JP).
SUZUKI, Hiroto; (JP)
Agent: SHIMIZU, Hatsushi; Kantetsu Tsukuba Bldg. 6F 1-1-1, Oroshi-machi Tsuchiura-shi, Ibaraki 3000847 (JP)
Priority Data:
2007-038498 19.02.2007 JP
Title (EN) AGENT FOR TREATMENT OF ADHD-RELATED DISEASES
(FR) AGENT DESTINÉ AU TRAITEMENT DE MALADIES ASSOCIÉES AU THADA
(JA) ADHD関連疾患治療剤
Abstract: front page image
(EN)Disclosed is an agent for treatment of ADHD-related diseases, which contains a compound represented by the formula (1) below or at least one pharmaceutically acceptable salt thereof as an active ingredient. (1) (In the formula, R1 and R2 independently represent a hydrogen atom, a hydroxy group, an alkyl group or an alkoxy group; and R3 represents a hydrogen atom, a hydroxy group, an alkyl group, an alkoxy group or a sugar residue.)
(FR)La présente invention concerne un agent destiné au traitement de maladies associées au THADA, qui contient un composé représenté par la formule (1) ci-dessous ou au moins l'un de ses sels acceptables sur le plan pharmaceutique en tant que principe actif. (1) (Dans la formule, R1 et R2 représentent indépendamment un atome d'hydrogène, un groupe hydroxy, un groupe alkyle ou un groupe alcoxy ; et R3 représente un atome d'hydrogène, un groupe hydroxy, un groupe alkyle, un groupe alcoxy ou un résidu de sucre.)
(JA) 本発明に係るADHD関連疾患治療剤は、下記構造式(1)の化合物またはその薬学的に許容される塩の少なくとも1種を有効成分として含有する。  式中、R及びRはそれぞれ独立して、水素原子、水酸基、アルキル基、またはアルコキシ基であり、Rは水素原子、水酸基、アルキル基、アルコキシ基、または糖残基である。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)